The global in vitro diagnostics market size is expected to reach USD 118.72 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 6.75% over the forecast period driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.
These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.
Request a free sample copy or view the report summary: In Vitro Diagnostics Market Report
Molecular diagnostics is anticipated to grow at the fastest CAGR from 2025 to 2030 owing to the rising adoption and usage rate
Reagents held the largest market share owing to the surge in demand for genetic testing and enhanced availability of technologically advanced diagnostic tests in lower and middle-income countries with unmet clinical needs
The infectious diseases application segment held the largest market share owing to the large volume of testing for infectious diseases globally
North America dominated the global market in 2024 owing to the high demand for novel technologies, a large pool of key players, high prevalence of diseases, and advanced healthcare infrastructure
Grand View Research has segmented the global in vitro diagnostics market report based on product, technology, application, end-use, test location, and region:
In Vitro Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)
Instruments
Reagents
Services
In Vitro Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)
Immunoassay
Instruments
Reagents
Services
Hematology
Instruments
Reagents
Services
Clinical Chemistry
Instruments
Reagents
Services
Molecular Diagnostics
Instruments
Reagents
Services
Coagulation
Instruments
Reagents
Services
Microbiology
Instruments
Reagents
Services
Others
Instruments
Reagents
Services
In Vitro Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)
Infectious Diseases
Diabetes
Oncology
Cardiology
Nephrology
Autoimmune Diseases
Drug Testing
Others applications
In Vitro Diagnostics Test Location Outlook (Revenue, USD Million, 2018 - 2030)
Point of Care
Home-care
Others
In Vitro Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Laboratory
Home-care
Others
In Vitro Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Spain
Italy
Russia
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Singapore
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the In Vitro Diagnostics Market
Abbott
bioMérieux SA
QuidelOrtho Corporation
Siemens Healthineers AG
Bio-Rad Laboratories, Inc.
Qiagen
Sysmex Corporation
Charles River Laboratories
Quest Diagnostics Incorporated
Agilent Technologies, Inc.
Danaher Corporation
BD
F. Hoffmann-La Roche Ltd.
"The quality of research they have done for us has been excellent..."